Transplantation of allogeneic CD34-selected stem cells after fludarabine-based conditioning regimen for children with mucopolysaccharidosis 1H (M. Hurler)

被引:22
作者
Grigull, L
Beilken, A
Schrappe, M
Das, A
Luecke, T
Sander, A
Stanulla, M
Rehe, K
Sauer, M
Schmid, H
Welte, K
Lukacs, Z
Gal, A
Sykora, KW
机构
[1] Hannover Med Sch, Childrens Hosp, Pediat Metab Dis Sect, Hannover, Germany
[2] Univ Hosp Hamburg Eppendorf, Dept Pediat, Metab Lab, Hamburg, Germany
[3] Univ Hosp Hamburg Eppendorf, Inst Human Genet, Hamburg, Germany
关键词
mucopolysaccharidosis; CD34+selection; donor lymphocyte infusion; fludarabine;
D O I
10.1038/sj.bmt.1704786
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Hurler syndrome (MPS1H) is a progressive inborn error of mucopolysaccharide metabolism leading to premature death. Allogeneic hematopoietic cell transplantation (HCT) can achieve stabilization and improve long-term survival. However, large studies have shown that preparative regimen-related toxicity (RRT) and graft failure rates have been relatively high. We transplanted five Hurler children with a fludarabine-based conditioning regimen, consisting of fludarabine/busulphan/ATG for matched family donor (MFD), with the addition of melphalan for mismatched family donor and matched unrelated donor ( MUD) transplantations. Median age at HCT was 27 months ( range 10 - 36). The source of stem cells was bone marrow in one MFD and CD34-selected PBSC in four patients. Median CD34+ cell dose was 25 x 10(6)/kg ( range 11.5 - 54). No RRT >grade II was observed. All patients are surviving at a median of 32 months ( range 14 - 41) and show sustained donor engraftment with 3/5 having full donor chimerism, and 2/5 mixed chimerism (>85%). W e conclude that this regimen is feasible and has low toxicity in Hurler children. In combination with high doses of CD34+ selected cells (>10 x 10(6)/kg) and donor lymphocyte infusions, stable engraftment could be achieved in unrelated and mismatched related transplantations.
引用
收藏
页码:265 / 269
页数:5
相关论文
共 32 条
[1]   Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children [J].
Bader, P ;
Klingebiel, T ;
Schaudt, A ;
Theurer-Mainka, U ;
Handgretinger, R ;
Lang, P ;
Niethammer, D ;
Beck, JF .
LEUKEMIA, 1999, 13 (12) :2079-2086
[2]   Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective [J].
Bader, P ;
Kreyenberg, H ;
Hoelle, W ;
Dueckers, G ;
Kremens, B ;
Dilloo, D ;
Sykora, KW ;
Niemeyer, C ;
Reinhardt, D ;
Vormoor, J ;
Gruhn, B ;
Lang, P ;
Greil, J ;
Handgretinger, R ;
Niethammer, D ;
Klingebiel, T ;
Beck, JF .
BONE MARROW TRANSPLANTATION, 2004, 33 (08) :815-821
[3]   Variable clinical presentation in lysosomal storage disorders [J].
Beck, M .
JOURNAL OF INHERITED METABOLIC DISEASE, 2001, 24 :47-51
[4]   FLUDARABINE PHOSPHATE - A SYNTHETIC PURINE ANTIMETABOLITE WITH SIGNIFICANT ACTIVITY AGAINST LYMPHOID MALIGNANCIES [J].
CHUN, HG ;
LEYLANDJONES, B ;
CHESON, BD .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (01) :175-188
[5]   Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results [J].
Dalle, JH ;
Wall, D ;
Theoret, Y ;
Duval, M ;
Shaw, L ;
Larocque, D ;
Taylor, C ;
Gardiner, J ;
Vachon, MF ;
Champagne, MA .
BONE MARROW TRANSPLANTATION, 2003, 32 (07) :647-651
[6]   Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin [J].
Finke, J ;
Bertz, H ;
Schmoor, C ;
Veelken, H ;
Behringer, D ;
Wäsch, R ;
Kunzmann, R ;
Heidecker, L ;
Lang, H ;
Meyer-König, U ;
Mertelsmann, R .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (01) :303-313
[7]   Outcome of second hematopoietic cell transplantation in Hurler syndrome [J].
Grewal, SS ;
Krivit, W ;
Defor, TE ;
Shapiro, EG ;
Orchard, PJ ;
Abel, SL ;
Lockman, LA ;
Ziegler, RS ;
Dusenbery, KE ;
Peters, C .
BONE MARROW TRANSPLANTATION, 2002, 29 (06) :491-496
[8]   Follow-up of nine patients with Hurler syndrome after bone marrow transplantation [J].
Guffon, N ;
Souillet, G ;
Maire, I ;
Straczek, J ;
Guibaud, P .
JOURNAL OF PEDIATRICS, 1998, 133 (01) :119-125
[9]   Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation [J].
Ho, VT ;
Weller, E ;
Lee, SJ ;
Alyea, EP ;
Antin, JH ;
Soiffer, RJ .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001, 7 (04) :223-229
[10]   Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children [J].
Jacobsohn, DA ;
Duerst, R ;
Tse, W ;
Kletzel, M .
LANCET, 2004, 364 (9429) :156-162